and identified a unique subset of patients whose disease paradoxically accelerated on immunotherapy. Herein, we describe our cohort of hyperprogressors.
Introduction
Immune checkpoint inhibitors are becoming standard of care for multiple cancer types. As experience grows with this therapeutics, anecdotal reports started relating rapid disease progressions, which could suggest that immune checkpoint blockade may have a deleterious effect by accelerating the disease in a subset of patients. Champiat et al. [1] defined the hyperprogressive disease (HPD) as a ≥2-fold increase of the tumor growth rate (TGR) between the REF and the EXP periods. Twelve patients (9%) were considered as having HPD. HPD was neither associated with higher tumor burden at baseline nor with any specific tumor type. At progression, patients with HPD had a lower rate of new lesions than patients with disease progression without HPD (P < 0.05). HPD is associated with a higher age (P < 0.05) and a worse outcome (overall survival [OS] ). Saâda-Bouzid et al. [2] defined hyperprogression in recurrent and/or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), treated with PD-1/PD-L1 inhibitors, as tumor growth kinetics R ≥2. Hyperprogression was observed in 29% of patients with R/M HNSCC treated with anti-PD-L1/PD-1 agents and correlated with a shorter progression-free survival. Kato et al. [3] defined hyperprogression as time-to-treatment failure (TTF) <2 months, >50% increase in tumor burden compared to preimmunotherapy imaging, and >2-fold increase in progression pace. After anti-PD-1/PD-L1 monotherapy, four of these patients showed remarkable increases in existing tumor size (55%-258%), new large masses, and significantly accelerated progression pace. Ferrara et al. [4] defined HPD as disease progression at the first evaluation with ΔTGR exceeding 50%. Fifty-six patients (13.8%) were classified as having HPD. HPD was significantly associated with more than two metastatic sites before PD-1/PD-L1 inhibitors compared with non-HPD (62.5% [35 of 56] vs. 42.6% [149 of 350]; P = 0.006).
Materials and Methods
We did a retrospective analysis of fifty patients treated with immunotherapy for different malignancies at our center How to cite this article: Abbas W, Rao RR, Popli S. Hyperprogression after immunotherapy. South Asian J Cancer 2019;8:244-6.
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Immuno Oncology ORIGINAL ARTICLE chemotherapy, he was started on nivolumab from December 2017 to January 2018 and received three cycles. He had weight loss, and repeat positron emission tomography-computed tomography (PET-CT) for assessment revealed new liver and lung lesions and 400% increase as per RECIST. Furthermore, pleural effusion was a new finding and qualified for hyperprogression [ Figures 1b and 2 ].
Case #3
A 60-year-old male was diagnosed with high-grade urothelial carcinoma of the left ureter in August 2015 and received four cycles of NACT with gemcitabine and carboplatin and underwent surgery (left nephrectomy and uretrectomy). 
Results
We analyzed a total of 50 patients treated with anti-PD-1 or anti-PD-L1 monotherapy. Patients without a baseline CT scan at the start of immunotherapy were excluded from the study. All three patients with urothelial carcinoma were on chemotherapy before the start of immunotherapy, and the patient with malignant melanoma was on follow-up. We compared TGR of tumor before starting immunotherapy for TGR during both the REF periods (i.e., most often, between the imaging examination indicating prior progression and baseline) and the EXP periods. All four cases qualified for hyperprogression as they have twofold increase in size and plus what we observed also they developed multiple bone and liver metastasis and very high tumor burden at the time of assessment. When we looked into survival data, there was a clear trend toward worse outcome for the patients with HPD (median OS, 3 months) [ Figure 3 ].
Discussion
For the first time ever, oncologists now face drugs with an extraordinary potential, but which also may induce a dramatic tumor surge in a fraction of patients. Overall, the HPD phenomenon with immune checkpoint blockade appears to be restricted to a small group of patients (~10%). We have seen in earlier studies with adjuvant interferon used for malignant melanoma. Those patients who died had a very reduced time from relapse to death. [5] Hence, the phenomenon of disease progression is not only associated with immunotherapy but also with other therapeutic agents as well. [6, 7] There could be oncogenic signal activation, and PD-1/PD-L1signalling has cell-intrinsic factors.
The striking acceleration of tumor disease observed in patients with HPD could suggest an oncogenic signaling activation. [8] It has been demonstrated that PD-1/PD-L1 signaling has cell-intrinsic functions in tumor cells. Immune compensatory mechanisms may play a role, and upregulation of alternative immune system can activate protumor immune subsets. [9, 10] We defined hyperprogression as > twofold increase in progression pace. We did not take hyperprogression as TTF <2 months into consideration because evaluation was done beyond 2 months for some patients.
In this study, four patients qualified for hyperprogression. Of four patients, three patients had urothelial carcinoma and one patient had malignant melanoma.
Chiampiat et al. showed patients with HPD exhibited a lower rate of new lesions than patients with non-HPD progression. Our study showed that apart from progression at primary site, there was florid progression at other sites as well, especially liver and bones.
One can always debate that in all the above-mentioned studies, [1] [2] [3] [4] immunotherapy was started as a treatment option in third-line or fourth-line settings, and this is the time where disease starts progressing very fast and the patients have few months to live. The biggest question remains, is this the natural history of disease or hyperprogression? Now, as checkpoint inhibitors are being used in first-line setting, we will have better understanding of hyperprogression. This question shall be addressed in the ongoing immunotherapy studies.
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monthly. In December 2018, after 21 cycles of the first-line chemotherapy, he complained of increasing pain in the abdomen. A restaging CT scan showed progressive disease with an increase in the liver lesions. After a progression-free interval of 11 months, his chemotherapy was changed capecitabine with irinotecan as the second line, considering his good performance status. Response evaluation after six cycles has revealed stable disease. However, in April 2019, he complained of dull-aching pain in the right thigh anterolateral aspect. Examination revealed a hard tender mass, fixed to the underlying bone. MRI of the thigh was done, which showed a vertically elongated oval altered signal intensity lesion in the intermuscular plane between the right vastus intermedius and right vastus lateralis in the proximal one-third of the right thigh as described -likely a metastatic deposit [ Figure 1b ]. Guided aspiration biopsy was done which showed deposits of metastatic adenocarcinoma, consistent with GBCA. He is still quite well preserved after 15 months of systemic chemotherapy and has been planned for the third-line chemotherapy with docetaxel.
Metastatic GBCA has very poor outcomes. Conventionally, the treatment of advanced GBCA was single-agent gemcitabine. After the report of the ABC 02 trial, doublet-agent gemcitabine with cisplatin (GEMCIS) became the standard with significant improvement in progression-free survival (PFS). The median PFS was 8.0 months in the cisplatin-gemcitabine group and 5.0 months in the gemcitabine-only group (P < 0.001). [6] A randomized trial by Sharma et al. from India showed that six cycles of mGEMOX is equivalent to eight cycles of GEMCIS and one of these may be chosen for initial treatment. [7] Another matched-pair analysis of mGEMOX and GEMCIS also showed that both have equal efficacy. [8] Our patient received standard chemotherapy with mGEMOX. He had a reasonable PFS of 15 months, even though the median PFS of GBCA is in the range of 4-6 months. [6, 7] (Continue on page 254...) the liver with heterogeneous peripheral enhancement and filling in on delayed sequences with peripheral restricted diffusion features, suggestive of GBCA. A small lesion in segment V of the liver was also seen, which was consistent with metastasis. Baseline staging with contrast computed tomography (CT) was done, which did not show any distant metastasis. A guided biopsy confirmed adenocarcinoma, consistent with GBCA. Focused exome sequencing revealed that he was positive for in-del mutation in exon 8 of the TP53 gene.
His routine complete blood counts were normal; renal function as well as liver functions were normal, except mildly elevated alkaline phosphatase of 465 (38-126) U/L. However, he did not have any bone pain. Considering the diagnosis of metastatic GBCA, he was started on systemic chemotherapy with palliative intent, with doublet gemcitabine and oxaliplatin (mGEMOX) from February 2018. He tolerated his chemotherapy cycles well.
After the first cycle of chemotherapy, he complained of pain in the right cheek with a hard painful swelling, leading to trismus. On examination, he has a hard swelling fixed to the masseter muscle. MRI of the face revealed a well-defined complex lesion measuring 1.7 cm × 1.7 cm × 1.6 cm with cystic and solid components within the buccal space anterior to the right masticator muscle and showed peripheral thick-walled enhancement postcontrast [ Figure 1a ]. Cytology from the mass revealed poorly differentiated adenocarcinoma, consistent with metastasis from GBCA. He was continued on systemic chemotherapy and was offered palliative radiotherapy to the buccal lesion, to which he responded well. After 6 cycles of chemotherapy, response evaluation was done, which showed stable disease. He was continued on the same regimen till cycle 11, after which he developed grade II peripheral motor neuropathy. Hence, oxaliplatin was stopped and he was maintained on gemcitabine, with response evaluation every 3 (Letter to the editor continue from page 240...)
